News
XENE
40.48
-1.26%
-0.52
Xenon Pharmaceuticals Earnings Call Signals Broad Pipeline Momentum
TipRanks · 3h ago
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Veeva Systems (VEEV) and Liquidia Technologies (LQDA)
TipRanks · 3d ago
Xenon Pharmaceuticals reports Q3 EPS ($1.11), consensus ($1.14)
TipRanks · 4d ago
Xenon: Undervalued Ahead of Azetukalner’s FDA Decision, with Pipeline and Liquidity Supporting Upside
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Xenon (XENE) and Perspective Therapeutics (CATX)
TipRanks · 4d ago
Needham Keeps Their Buy Rating on Xenon (XENE)
TipRanks · 4d ago
Xenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2
NASDAQ · 4d ago
Analyst Reiterates Buy on Azetukalner’s Clinical Promise, Maintains $74 Price Target
TipRanks · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Xenon (XENE), Ocular Therapeutix (OCUL)
TipRanks · 4d ago
Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 5d ago
Xenon Pharmaceuticals Inc. Reports Q3 2026 Financial Results and Business Update
NASDAQ · 5d ago
Xenon Pharma GAAP EPS of -$1.11 beats by $0.03
Seeking Alpha · 5d ago
Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate
Benzinga · 5d ago
*Xenon Pharmaceuticals 3Q Loss/Shr $1.11 >XENE
Dow Jones · 5d ago
Xenon Pharmaceuticals: Q3 Earnings Snapshot
Barchart · 5d ago
Weekly Report: what happened at XENE last week (1102-1106)?
Weekly Report · 5d ago
Xenon's NDA Already Sitting on the FDA's Desk
Barchart · 11/06 16:20
Xenon to Present at Four Healthcare Investor Conferences
TipRanks · 11/03 22:04
Xenon to Report Third-Quarter 2026 Results November 9
TipRanks · 11/02 21:52
Weekly Report: what happened at XENE last week (1026-1030)?
Weekly Report · 11/02 09:23
More
Webull provides a variety of real-time XENE stock news. You can receive the latest news about Xenon Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.